For instance, the top 1 gene in DhMRs between CRC patients and HCs was TP63, a new promising therapeutic member of the well‐known TP53 family, which can suppress tumor cell growth, induce cell apoptosis, and cooperate with chemotherapy with low dose and less side effects [36]. This evidence concerns the gene TP63 and colorectal carcinoma.